Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Date:10/4/2007

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet.

The study, "Soy protein isolate increases urinary estrogens and the ratio of 2:16 alpha-hydroxyestrone in men at high risk of prostate cancer," is believed to be the first study investigating the effects of soy protein consumption on estrogen metabolism and prostate cancer in men.

"The intent of the study was to evaluate the effects of consuming soy protein on elimination of estrogen metabolites in the urine of men at a high risk for prostate cancer," said Dr. Mindy Kurzer, lead author of the study and a professor in the Department of Food Science and Nutrition at the University of Minnesota. "After taking biopsies of prostate tissue, androgen receptors were reduced in the prostate, which is consistent with a reduced risk of prostate cancer. In addition, significantly fewer of the men who consumed soy protein progressed to cancer by the end of the six-month study. We are encouraged by the results, but more studies must be performed."

"The results of this study could be beneficial for men who are at risk of prostate cancer," said Dr. Kathryn Greaves, Group Lead, Clinical Nutrition at Solae. "If the results of this study are replicated in future studies, reducing the risk of prostate cancer may be another reason to include soy in your daily diet."

Soy has been documented to potentially improve heart health and aid in sports performance and weight management. For more information on Solae and its products, please visit http://www.solae.com.

About Solae

Solae is the world leader in developing innovative soy-based technology to the food, meat and nutritional products industries. Solae provides solutions that deliver a un
'/>"/>

SOURCE Solae
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...OUSTON, Nov. 9 Patent attorneys C...ala, Ph.D., J. D., will showcase Stipkala LLC at t...009, which will be held at the Institute of Molecu...ce Conference provides a platform for cutting-edge... to investors, and will feature keynote addresses ...
(Date:11/9/2009)...EW YORK, Nov. 9 MISSION Skincare&#...ennis star Serena Williams, soccer professional Mi...unching "Active Lifestyle Skincare Destinations" i... locations across the country beginning this week....are products, MISSION and CVS/pharmacy have set ou...
(Date:11/9/2009)...OCKVILLE, Md., Nov. 9 OriGene Tech...Technology in Sweden has adopted its VERIFY Tagged...n Protein Atlas program. This program is funded by...et up to explore the human proteome systematically... quality mono-specific antibodies in a high throug...
Breaking Medicine Technology:Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2Hologic to Host Investor Reception at RSNA 2009 5607 1Hologic to Host Investor Reception at RSNA 2009 5607 2Premier Research Names Bernard Sweeney as Executive Director Medical Devices 5602 1Premier Research Names Bernard Sweeney as Executive Director Medical Devices 5602 2Babies Injured in Car Seats Used Outside of Cars 59817 1Babies Injured in Car Seats Used Outside of Cars 59817 2Babies Injured in Car Seats Used Outside of Cars 59817 3
...earchers report that a,variation in a portion of D... this common variation may be responsible for up t... in the United States.,The research was conducted ...e (NCI), part of the National Institutes of Health... of Susceptibility,(CGEMS) initiative. CGEMS resea...
...l 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys,...its second multi-center Phase 2 trial of GVAX,immu...lating doses,of the immunotherapy in 80 patients w...(HRPC). Additional follow-up of,the 22 patients wh...ng employed in the company,s ongoing Phase 3 progr...
Other Medicine Technology:Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 2Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 3Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 4Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:11/9/2009)...na, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat ...d today that Novartis, a US$41 billion internation...n HTDS, H1N1 Vaccine partner, Zhejiang Tianyuan Bi...vartis of Switzerland will begin a five-year, $1 b... will dramatically increase its investment in its ...
(Date:11/9/2009)... Course, to be Offered in April 2010, Provid... Cambridge, MA (Vocus) Novembe... Human Rights (PHR) first inspected a suspected m...lized he would need a team of experts to help inte... properly was a key first step in securing evidenc...
(Date:11/9/2009)... Calif., Nov. 9 Actress Mariska Ha... philosophy on Saturday to raise awareness abou...throughout California by building healing and well...ts were created to give one to each of the estimat...Angeles County,s domestic violence shelters. ,,...
(Date:11/9/2009)... 9 Highlighting a commitment to pr...anced entertainment and digital display technology...Long-Term Care and Hospital Grade LCD HDTVs this w...he Aging 2009 annual meeting and exposition (booth...ine of "HealthView(TM)" Long-Term Care LCD HDTVs b...
(Date:11/9/2009)... some people went from incapacitated to working ag...ws) -- Electrical stimulation of a certain area of...vere depression, say German researchers. , They...a of the brains of 10 people. This area of the br... people remember good experiences and puts them in...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2
...lished in,a major national journal reports the ann...led over the last six years. But experts at U.S.,P...ntion services, say the,actual costs are far highe.../NETU129LOGO ), "According to the study in the A...
...BOVESPA: MEDI3) (MEDIAL SAUDE) announces the follo...Quarter 2008 Earnings Conference Call, When: ... http://prnewswire.isat.com.br/?palestra_id=42... web at the address above., ...
... leading researchers in academia and industry from...discovery of method for promoting HEK 293 cell gro...lostrum. , Fort Collins, ... benefit of using recombinant lactoferrin (Lacromi...
...s Annual Meeting, Chicago, Oct. 28 Sgt. Robert B...and motivational speaker and mentor,for wounded ve...tients of,Courage: Triumph Over Adversity Award, a...h Over Adversity program honors,reconstructive pla...
...achers Build Community Connections in .... 28 Teach For America and,Eli Lilly and Company ...,new teachers working in the city,s low-income com...e Lilly employee,advocates and Teach For America t...
...LPHIA, Oct. 28 Blood stored for 29 days or more,n...lood storage, is,associated with a higher infectio...the blood. In a new study presented at CHEST 2008,...ansfusions with blood stored for 29 days or more w...
Other Medicine News:Health News:U.S. Preventive Medicine Says Prevention Can Keep Diabetes Costs From Rising 2Health News:Webcast Alert: Medial Saude S/A Announces Third Quarter 2008 Earnings Conference Call Webcast 2Health News:Global Scientific Research Collaboration Leads to Breakthrough in Culturing HEK 293 Cells in Animal-free Media 2Health News:Gilbert Resident, Iraq War Hero Wins Patient of Courage Award 2Health News:Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools 2Health News:Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools 3Health News:'Old Blood' Linked To Infection 2Health News:'Old Blood' Linked To Infection 3
...L delivers the widest field of view of any lens e...ovides simultaneous visualization of the posterior...r margin of safety during pan retinal photocoagula... visualization and treatment of proliferative diab...
... provides ultra wide-field viewing and outstanding...undus exams at the slit lamp. It has been specific...ugh small pupils without the hassle and steep lear...ng an incredible 124° dynamic field of view wi...
...arted the slit lamp examination revolution! It fea...utstanding for dynamic fundoscopy. Volk's exclusiv...e viewing field beyond that of competitive designs...making it ideal for a quick look at the posterior ...
40D
Medicine Products: